Cite
HARVARD Citation
Janku, F. et al. (2023). A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF‐10502‐01 for the treatment of advanced solid tumors. Cancer. 129 (10), pp. 1537-1546. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Janku, F. et al. (2023). A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF‐10502‐01 for the treatment of advanced solid tumors. Cancer. 129 (10), pp. 1537-1546. [Online].